Twist Bioscience (NASDAQ:TWST) CAO Sells $20,039.20 in Stock

Twist Bioscience Corporation (NASDAQ:TWST) CAO Robert Werner sold 148 shares of Twist Bioscience stock in a transaction on Tuesday, November 3rd. The stock was sold at an average price of $135.40, for a total transaction of $20,039.20. Following the transaction, the chief accounting officer owned 42,769 shares in the company, valued at $5,790,922.60. This represents a 0.34% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Twist Bioscience Stock Performance

Shares of NASDAQ:TWST traded down $22.05 during midday trading on Thursday, hitting $120.53. The company had a trading volume of 3,084,289 shares, compared to its average volume of 1,763,809. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.67 and a quick ratio of 2.38. The company has a market cap of $7.56 billion, a price-to-earnings ratio of -54.29 and a beta of 2.25. Twist Bioscience Corporation has a 12-month low of $23.30 and a 12-month high of $219.71. The company has a fifty day moving average of $152.59 and a two-hundred day moving average of $90.28.

Twist Bioscience (NASDAQ:TWST) last announced its earnings results on Monday, August 3rd. The company reported ($0.56) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.05). The company had revenue of $118.38 million during the quarter, compared to the consensus estimate of $114.55 million. Twist Bioscience had a negative return on equity of 28.64% and a negative net margin of 31.66%. Twist Bioscience’s revenue for the quarter was up 23.2% compared to the same quarter last year. During the same period in the prior year, the business posted $0.33 earnings per share. On average, equities research analysts expect that Twist Bioscience Corporation will post -2.12 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

TWST has been the topic of several recent research reports. Guggenheim raised their price objective on Twist Bioscience from $107.00 to $212.00 and gave the stock a “buy” rating in a research note on Thursday, October 1st. Piper Sandler increased their target price on shares of Twist Bioscience from $85.00 to $115.00 and gave the stock an “overweight” rating in a report on Wednesday, August 5th. Jefferies Financial Group started coverage on shares of Twist Bioscience in a research note on Thursday, October 8th. They set a “hold” rating and a $150.00 target price on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Twist Bioscience in a report on Monday, September 21st. Finally, UBS Group began coverage on shares of Twist Bioscience in a research note on Wednesday, September 9th. They issued a “neutral” rating and a $144.00 price objective for the company. Seven investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, Twist Bioscience presently has an average rating of “Hold” and an average target price of $153.00.

Institutional Trading of Twist Bioscience

A number of institutional investors and hedge funds have recently bought and sold shares of TWST. Western Wealth Management LLC purchased a new position in shares of Twist Bioscience during the first quarter valued at about $31,000. Strs Ohio bought a new stake in shares of Twist Bioscience in the first quarter worth about $33,000. Root Financial Partners LLC purchased a new stake in shares of Twist Bioscience in the third quarter worth about $33,000. PNC Financial Services Group Inc. raised its holdings in shares of Twist Bioscience by 89.7% during the 1st quarter. PNC Financial Services Group Inc. now owns 958 shares of the company’s stock worth $46,000 after acquiring an additional 453 shares in the last quarter. Finally, Fifth Third Bancorp purchased a new stake in Twist Bioscience during the first quarter valued at $54,000.

Twist Bioscience Company Profile

Twist Bioscience Corporation is a biotechnology company that develops and manufactures synthetic DNA and related products for life sciences research. The company uses a proprietary silicon-based platform to produce high-quality DNA at scale, supporting applications in synthetic biology, drug discovery and development, agriculture, and academic and industrial research.

Its offerings include synthetic genes, oligonucleotides, gene fragments, variant libraries, and antibody discovery products.